Company intelligence / Profile preview
Ocean Biomedical
- Ownership
- Public · OCEA
- Employees
- ~7
- Development stage
- Other
Overview
Ocean Biomedical is developing multiple therapeutic candidates including anti-CHI3L1 antibodies for cancer immunotherapy, malaria treatments targeting PfGARP, and therapies for pulmonary fibrosis. Recent publications have deepened understanding of their novel cancer immunotherapy approach targeting CHI3L1 and its ability to inhibit anti-tumor responses. A key U.S. patent was issued for PfGARP malaria antibodies central to their malaria treatment and prevention platforms[1][2].
- Therapeutic areas
- OncologyPulmonologyRare DiseasesInfectious Diseases
- Modalities
- Antibody therapeuticssmall moleculesvaccinesbi-specific antibodies
- Industry
- Biotech
Drug pipeline
13 assets12 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $237.3K
- Total revenue
- $0
- Enterprise value
- $8.8M
Beyond the preview
Go deeper on Ocean Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ocean Biomedical.